1LLY:BIT
Eli Lilly and Company
1 017,40 €
arrow_downward
-0,57%(-5,80) 1 d.
2. okt., 17:29:23 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: 1LLY…
Atvērt
1 023,60 €
Augsta
1 031,00 €
Zema
1 016,00 €
Tirgus kapitalizācija
1,11 trilj.
Vid. apjoms
382,00
Apjoms
492,00
Augstākā 52 ned.
1 106,80 €
Zemākā 52 ned.
640,70 €
Darbinieku skaits
50 tūkst.
Atvērt
1 023,60 €
Augsta
1 031,00 €
Zema
1 016,00 €
Tirgus kapitalizācija
1,11 trilj.
Vid. apjoms
382,00
Apjoms
492,00
Augstākā 52 ned.
1 106,80 €
Zemākā 52 ned.
640,70 €
Darbinieku skaits
50 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
AD HOC NEWS
·
pirms 25 minūtēm
Eli Lilly stock enters weekly review with 21 dermatology presentations
Yahoo Finance
·
pirms 20 stundām
Eli Lilly’s Biggest Shareholder Just Filed to Sell $347 Million of Stock
Stock Titan
·
pirms 22 stundām
Lilly’s two medicines were linked to changes in 482 blood proteins, versus 140 with Taltz alone.
Stock Traders Daily
·
pirms 1 dienas
Discipline and Rules-Based Execution in LLY Response
Profils
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Par “Eli Lilly and Company”
ĢenerāldirektorsDavid A. Ricks
Darbinieki50 tūkst.
Dibināšanas datums1876
Galvenais birojsIndianapolisa, Indiāna, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnelilly.com